Bank of New York Mellon Corp Trims Holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Bank of New York Mellon Corp reduced its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 6.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 437,515 shares of the life sciences company’s stock after selling 30,447 shares during the quarter. Bank of New York Mellon Corp owned 0.57% of Integra LifeSciences worth $9,621,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Quadrant Capital Group LLC boosted its position in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 1,371 shares in the last quarter. Sterling Capital Management LLC increased its stake in Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 1,931 shares in the last quarter. Covestor Ltd increased its stake in Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock valued at $123,000 after purchasing an additional 2,071 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in Integra LifeSciences during the 1st quarter valued at $223,000. Finally, NorthRock Partners LLC acquired a new stake in Integra LifeSciences during the 4th quarter valued at $251,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JMP Securities reduced their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday, May 9th. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. JPMorgan Chase & Co. lowered their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. Finally, Wells Fargo & Company lowered their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $18.63.

Integra LifeSciences Stock Up 2.2%

Integra LifeSciences stock opened at $11.37 on Tuesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.21 and a quick ratio of 0.72. The business has a 50 day simple moving average of $12.70 and a 200-day simple moving average of $18.28. The stock has a market capitalization of $883.56 million, a PE ratio of 4.60, a price-to-earnings-growth ratio of 0.62 and a beta of 1.15. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $32.49.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company had revenue of $382.65 million for the quarter, compared to analysts’ expectations of $381.17 million. During the same quarter last year, the company earned $0.55 EPS. Integra LifeSciences’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.